TERZAH HORTON to Adult
This is a "connection" page, showing publications TERZAH HORTON has written about Adult.
Connection Strength
0.216
-
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 07; 186(2):274-285.
Score: 0.035
-
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22.
Score: 0.027
-
A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92.
Score: 0.017
-
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
Score: 0.016
-
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
Score: 0.013
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
Score: 0.013
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.
Score: 0.012
-
DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023 Mar 20; 24(6).
Score: 0.012
-
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci. 2023 Mar 13; 24(6).
Score: 0.012
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
Score: 0.011
-
IL-10 and TNFa are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatr Hematol Oncol. 2023 Mar; 40(2):147-158.
Score: 0.011
-
Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286.
Score: 0.008
-
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999.
Score: 0.008
-
Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995 Oct; 45(10):1879-83.
Score: 0.007
-
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7.
Score: 0.006
-
Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
Score: 0.006
-
Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995 May 24; 1271(1):141-51.
Score: 0.002
-
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992 Dec; 2(4):324-9.
Score: 0.001